Menu
Search
|

Menu

Close
X

Caladrius Biosciences Inc CLBS.OQ (NASDAQ Stock Exchange Capital Market)

2.33 USD
-0.01 (-0.43%)
As of 11:28 AM EDT
Previous Close 2.34
Open 2.36
Volume 603
3m Avg Volume 5,805
Today’s High 2.36
Today’s Low 2.30
52 Week High 6.83
52 Week Low 2.18
Shares Outstanding (mil) 10.38
Market Capitalization (mil) 30.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.436
FY18
-1.672
FY17
-1.796
FY16
-4.930
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
0.87
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-36.38
12.69
Return on Equity (TTM)
vs sector
-38.73
17.13

EXECUTIVE LEADERSHIP

David Mazzo
President, Chief Executive Officer, Director, Since 2017
Salary: $576,501.00
Bonus: $346,502.00
Joseph Talamo
Chief Financial Officer, Senior Vice President, Since 2015
Salary: $316,110.00
Bonus: $103,633.00
Douglas Losordo
Chief Medical Officer, Since 2013
Salary: $428,410.00
Bonus: $348,501.00
Gregory Brown
Director, Since 2016
Salary: --
Bonus: --
Cynthia Schwalm
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

110 Allen Rd
BASKING RIDGE   NJ   07920-4500

Phone: +1908.8420100

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

SPONSORED STORIES